Answers are grounded in this paper and cite their sources.
In this issue of the Journal, Sueta and co-authors[1] report a sub-analysis from the COMMAND VTE Registry 2 regarding the safety and efficacy of direct oral anticoagulants (DOACs) in patients with cancer-associated venous thromboembolism (VTE). The study included 1,197 patients with active cancer treated with edoxaban (n = 643, 54%), rivaroxaban (n = 297, 25%), and apixaban (n = 257, 22%). Despite adjusting for confounders, the risks of recurrent VTE and all-cause death did not differ significantly among the groups. Regarding bleeding events, the 5-year incidence of major and clinically relevant bleeding was lower in the rivaroxaban group than with other DOACs (22.6, 14.0, and 22.8%, p = 0.04; and 37.6, 26.8, and 38.3%, p = 0.01, respectively). This result was mitigated by adjustment for confounders.
No takes yet. Share an insight, caveat, or question.
Pastori et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: